Advertisement
Research Article

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

  • Mahiuddin Ahmed,

    Affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Yehuda Goldgur,

    Affiliation: Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Jian Hu,

    Affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Hong-Fen Guo,

    Affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Nai-Kong V. Cheung mail

    cheungn@mskcc.org

    Affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

    X
  • Published: May 16, 2013
  • DOI: 10.1371/journal.pone.0063359

About the Authors

Mahiuddin Ahmed, Jian Hu, Hong-Fen Guo, Nai-Kong V. Cheung
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
Yehuda Goldgur
Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America

Corresponding Author

Email: cheungn@mskcc.org

Competing Interests

Two of the authors (MA and NKC) were named as inventors on a patent for humanized monoclonal antibody 3F8.

Author Contributions

Conceived and designed the experiments: MA NKC. Performed the experiments: MA YG JH HFG. Analyzed the data: MA YG NKC. Contributed reagents/materials/analysis tools: YG NKC. Wrote the paper: MA.